Group 1 - Xuedilong plans to invest no more than 400 million yuan to build an innovation industrial base in Changping District, Beijing, focusing on chromatography and mass spectrometry production lines [1] - The project aims to enhance research and production capabilities in carbon monitoring and measurement systems [1] Group 2 - Zejing Pharmaceutical's tri-specific antibody drug ZGGS34 has received clinical trial approval from the National Medical Products Administration for treating MUC17 positive advanced solid tumors [2] - The drug shows strong anti-tumor activity and good safety in preclinical studies [2] Group 3 - Aosaikang's new cMET inhibitor ASK202 will present clinical research data at the 2025 ESMO annual meeting, showing an objective response rate of 68.8% and a disease control rate of 93.8% in advanced non-small cell lung cancer patients [2][3] Group 4 - China Life expects a net profit of 156.785 billion to 177.689 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 50% to 70% [4] Group 5 - Silan Microelectronics plans to jointly invest 5.1 billion yuan to build a 12-inch high-end analog chip production line, with a total project investment of 20 billion yuan [5][6] Group 6 - New City intends to use 156.65 million yuan of remaining fundraising to invest in a "Building Green Energy and Zero Carbon Park" project, with a total investment of 257 million yuan [8] Group 7 - Yidao Information plans to acquire control of Guangzhou Langguo Electronic Technology and Shenzhen Chengwei Information through a combination of share issuance and cash payment [9] Group 8 - Xiling Information's controlling shareholder has received a notice of lifting restrictions, allowing normal business operations to resume [10] Group 9 - Dongpeng Holdings' first batch of rock slab products has passed the highest level 5A quality inspection, becoming one of the first companies to meet the new national standard [11] Group 10 - Aonlikang's levofloxacin tablets have received approval from the National Medical Products Administration, classified as a chemical drug of category 4 [15] Group 11 - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance declaration revoked by the EU, confirming compliance with EU GMP requirements [17][18] Group 12 - Hongfuhan's shareholder plans to reduce its stake by up to 1.5% through various trading methods due to asset integration and funding needs [19] Group 13 - Purang Co. plans to establish a wholly-owned subsidiary in Hong Kong to enhance its international competitiveness and service levels [20] Group 14 - Tianhe Magnetic Materials' subsidiary has signed an investment agreement for a project worth 850 million yuan focused on high-performance rare earth permanent magnets [22] Group 15 - Xiangfenghua reported a 64.64% year-on-year decline in net profit for the first three quarters, despite an 8.16% increase in revenue [23] Group 16 - Darui Electronics reported a 26.84% year-on-year increase in net profit for the first three quarters, with total revenue growing by 28.59% [24] Group 17 - Xiangsheng Medical reported a 4.56% year-on-year decline in net profit for the first three quarters, despite a 41.95% increase in net profit for the third quarter [25]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：003012 证券简称：东鹏控股 公告编号:2025-078 广东东鹏控股股份有限公司 关于首批通过消费品质量分级5A级检测的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 国家标准GB/T 45817-2025《消费品质量分级 陶瓷砖》（以下简称"新国标"）将于2025年12月1日正式实 施，广东东鹏控股股份有限公司（以下简称"公司"）作为主导起草单位之一，参与了标准的调研、编 制、审核及验证全过程。近日，公司获得由佛山市质量计量监督检测中心检测和签发的检验报告，公司 首批送检的东鹏岩板产品符合新国标AAAAA级的要求，成为行业首批通过陶瓷砖新国标最高等级5A级 检测的企业。现将公司本次通过5A级检测的具体情况公告如下： 二、对公司的影响 国家标准GB/T 45817-2025《消费品质量分级 陶瓷砖》为陶瓷砖产品质量确立了统一的分级准则，最高 等级为AAAAA级，代表国际领先的质量水平。该标准的发布实施将加快新一轮标准升级，助力大宗消 费品更新换代，引导企业提升产品质量，促进产业转型升级，形 ...

Core Viewpoint - Dongpeng Holdings (003012) has announced that its first batch of Dongpeng rock slab products has passed the new national standard AAAA grade testing, making it one of the first companies in the industry to achieve the highest level 5A certification for ceramic tiles [1] Group 1 - The company received a testing report from the Foshan Quality Measurement Supervision and Inspection Center [1] - The products meet the requirements of the new national standard AAAA grade [1] - The achievement positions the company as a leader in the industry for compliance with the highest standards [1]

Core Viewpoint - Dongpeng Holdings (003012.SZ) announced that the national standard GB/T45817-2025 for quality grading of ceramic tiles will be officially implemented on December 1, 2025, with the company being one of the main drafting units involved in the entire process of research, preparation, review, and verification of the standard [1] Group 1 - The company has received a testing report from the Foshan Quality Measurement Supervision and Inspection Center, confirming that its first batch of Dongpeng rock slab products meets the new national standard's AAAA grade requirements [1] - Dongpeng Holdings is among the first companies in the industry to pass the highest level 5A testing of the new ceramic tile national standard [1]

东鹏控股公告，公司作为主导起草单位之一，参与了新国标GB/T 45817-2025《消费品质量分级陶瓷 砖》的调研、编制、审核及验证全过程。近日，公司首批送检的东鹏岩板产品符合新国标AAAAA级的 要求，成为行业首批通过陶瓷砖新国标最高等级5A级检测的企业。这标志着公司具备5A级质量等级的 产品研发、制造技术及品质管控的综合能力和水平，有助于产品结构优化与经营质量提升，为高质量发 展注入新动能。同时，有利于提升"东鹏"品牌的市场公信力和美誉度，巩固公司在建筑陶瓷行业的领军 企业地位。 ...